Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Barry McCook"'
Autor:
Nick Figura, MD, Stella Flampouri, PhD, Nancy P. Mendenhall, MD, Christopher G. Morris, MS, Barry McCook, MD, Savas Ozdemir, MD, William Slayton, MD, Eric Sandler, MD, Bradford S. Hoppe, MD, MPH
Publikováno v:
Advances in Radiation Oncology, Vol 2, Iss 2, Pp 197-203 (2017)
Purpose: This study analyzed the impact of pretreatment positron emission tomography/computed tomography (PET/CT) scans on involved site radiation therapy (ISRT) field design and pattern of relapse among patients with Hodgkin lymphoma (HL). Methods a
Externí odkaz:
https://doaj.org/article/167ea8cfc20d4e90a385867bf016ec34
Publikováno v:
Case Reports in Endocrinology, Vol 2015 (2015)
Objective. To present a complicated case of differentiated thyroid carcinoma (DTC) with metastases to the skull that was evident on I-131 whole body scan (WBS) but negative on other imaging modalities in a low risk patient. Methods. We will discuss c
Externí odkaz:
https://doaj.org/article/a4a49e8ba88242379739bcaa7ec8e4e8
Publikováno v:
Journal of Clinical Imaging Science
Objectives: The objectives of this study are to assess the utility of whole-body 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) (skull vertex to toes) imaging relative to the standard field of view (skull bas
Autor:
Nancy P. Mendenhall, William B. Slayton, Christopher G. Morris, Barry McCook, Bradford S. Hoppe, Eric Sandler, Nick Figura, Savas Ozdemir, Stella Flampouri
Publikováno v:
Advances in Radiation Oncology
Advances in Radiation Oncology, Vol 2, Iss 2, Pp 197-203 (2017)
Advances in Radiation Oncology, Vol 2, Iss 2, Pp 197-203 (2017)
Purpose This study analyzed the impact of pretreatment positron emission tomography/computed tomography (PET/CT) scans on involved site radiation therapy (ISRT) field design and pattern of relapse among patients with Hodgkin lymphoma (HL). Methods an
Autor:
Randal H. Henderson, Dat C. Pham, Zuofeng Li, Abubakr A. Bajwa, Harry J. D'Agostino, Bradford S. Hoppe, Barry McCook, Romaine C. Nichols, Soon Huh, Christopher G. Morris, James Cury, S. Flampouri
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 95:517-522
Purpose Proton therapy has been shown to reduce radiation dose to organs at risk (OAR) and could be used to safely escalate the radiation dose. We analyzed outcomes in a group of phase 2 study patients treated with dose-escalated proton therapy with
Publikováno v:
Journal of Clinical Imaging Science. 10:47
Objectives: The objectives of this study are to assess the utility of whole-body 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) (skull vertex to toes) imaging relative to the standard field of view (skull bas
Publikováno v:
PET Clinics. 2:433-443
Combined PET/CT has been in existence clinically for nearly 7 years since development and initial evaluation from 1998 to 2001. Combined PET/CT offers advantages over PET and CT acquired on separate devices, including consolidation of imaging studies
Publikováno v:
Case Reports in Endocrinology
Case Reports in Endocrinology, Vol 2015 (2015)
Case Reports in Endocrinology, Vol 2015 (2015)
Objective. To present a complicated case of differentiated thyroid carcinoma (DTC) with metastases to the skull that was evident on I-131 whole body scan (WBS) but negative on other imaging modalities in a low risk patient.Methods. We will discuss cl
Publikováno v:
Seminars in Nuclear Medicine. 36:157-168
Combined positron emission tomography/computed tomography (PET/CT) became FDA-approved for clinical use in late 2001. There are several design advantages of combined PET/CT over PET and CT acquired on separate devices, including more accurate CT and
Full-Dose 90Y Ibritumomab Tiuxetan Therapy Is Safe in Patients with Prior Myeloablative Chemotherapy
Autor:
Samuel A. Jacobs, Nicholas Vidnovic, Norbert Avril, Judith M. Joyce, Barry McCook, Frank Torok
Publikováno v:
Clinical Cancer Research. 11:7146s-7150s
Purpose: Targeted radioimmunotherapy with yttrium-90 (90Y)–labeled ibritumomab tiuxetan (Zevalin, IDEC-Biogen, San Diego, CA) has shown significant activity in the treatment of relapsed or refractory CD20+ non–Hodgkin's lymphoma. Eligibility crit